<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04782791</url>
  </required_header>
  <id_info>
    <org_study_id>R3</org_study_id>
    <nct_id>NCT04782791</nct_id>
  </id_info>
  <brief_title>Nivolumab, S-1 Combined With Oxaliplatin Versus Nivolumab as Neoadjuvant Therapy in Advanced Gastric Cancer</brief_title>
  <official_title>A Prospective, Randomized, Controlled Phase II Evaluation of Nivolumab, S-1 Combined With Oxaliplatin (Nivo+SOX) Versus Nivolumab (Nivo) as Neoadjuvant Therapy in Patients With Locally Advanced Gastric Adenocarcinoma (RESONANCE-Ⅲ Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is a prospective, randomized, controlled phase Ⅱ study which will be conducted in&#xD;
      Chinese PLA General Hospital, Beijing, China. Patients with eligibility will enrolled and&#xD;
      assigned into either group A for 9 weeks of nivolumab, S-1 combined with oxaliplatin&#xD;
      (Nivo+SOX) followed by D2 surgery and group B for 9 weeks of nivolumab followed by D2&#xD;
      surgery. The primary endpoint is the safety assessed by recording adverse events and the&#xD;
      secondary endpoints are response rate, disease control rate, pathological complete response&#xD;
      rate, D2 rate and R0 rate.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>The safety is assessed by recording adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RR</measure>
    <time_frame>2 years</time_frame>
    <description>Response rate, defined as the rate of patients who achieve CR or PR according to the RESIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>2 years</time_frame>
    <description>Disease control rate, defined as the rate of patients who achieve CR, PR or PD according to the RESIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pCR rate</measure>
    <time_frame>2 years</time_frame>
    <description>Pathological complete response rate, defined as the rate of patients achieving pathological complete response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D2 rate</measure>
    <time_frame>2 years</time_frame>
    <description>The rate of patients who received D2 radical gastrectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 rate</measure>
    <time_frame>2 years</time_frame>
    <description>The rate of patients who received R0 resection.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Chemotherapy Effect</condition>
  <arm_group>
    <arm_group_label>Nivo + SOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab plus SOX</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nivolumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab plus SOX</intervention_name>
    <description>The preoperative therapy consists of three-week cycles of intravenously administered nivolumab 360mg and oxaliplatin 130mg/m2 on day 1, and orally administered S-1 40-60 mg twice a day (BID) on day 1 to 14. The dose of S-1 depends on body surface area (BSA): BSA&lt;1.25 m2, 40mg; 1.25&lt;BSA&lt;1.50 m2, 50mg; BSA&gt;1.50 m2, 60mg. Day 15 to day 21 is the rest period.</description>
    <arm_group_label>Nivo + SOX</arm_group_label>
    <other_name>Nivo + SOX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>The preoperative therapy consists of three-week cycles of intravenously administered nivolumab 360mg on day 1.</description>
    <arm_group_label>Nivo</arm_group_label>
    <other_name>Nivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Gastrectomy</intervention_name>
    <description>A standard D2 radical laparoscopic gastrectomy according to the CSCO clinical guidelines for the diagnosis and treatment of gastric cancer is planned 3-4 weeks after the last cycle of preoperative therapy.</description>
    <arm_group_label>Nivo</arm_group_label>
    <arm_group_label>Nivo + SOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Non-bedridden, aged 18 to 70 years old;&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) score is 0 to 1;&#xD;
&#xD;
          -  Histologically confirmed gastric adenocarcinoma;&#xD;
&#xD;
          -  Have evaluable lesions based on RECIST 1.1;&#xD;
&#xD;
          -  Stage III (cT3-4aN1-3 M0, American Joint Committee on Cancer (AJCC) TNM staging system&#xD;
             8th edition) gastric cancer confirmed by enhanced computer tomography (enhanced CT)&#xD;
             and laparoscopic exploration (endoscopic ultrasonography (EUS) and magnetic resonance&#xD;
             imaging (MRI) if necessary);&#xD;
&#xD;
          -  The surgeon have the ability to complete standard D2 radical gastrectomy and the&#xD;
             gastrectomy can be tolerated by the patient;&#xD;
&#xD;
          -  Laboratory test criteria: peripheral blood hemoglobin (Hb) ≥ 90 g/L, neutrophil&#xD;
             absolute count ≥ 3× 109 /L, platelet count (PLT) ≥ 100× 109 /L, alanine&#xD;
             aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times the upper&#xD;
             limit of normal (ULN), total bilirubin ≤ 1.5×ULN, serum creatinine (SCr) ≤ 1.5×ULN,&#xD;
             and serum albumin (ALB) ≥ 30 g/L;&#xD;
&#xD;
          -  Patients with heart disease, echocardiogram showing that the left ventricular ejection&#xD;
             fraction ≥ 50%, electrocardiogram (ECG) is basically normal within 4 weeks before&#xD;
             operation and with no obvious symptoms are acceptable;&#xD;
&#xD;
          -  There is no serious underlying disease that could lead to an expected life expectancy&#xD;
             &lt; 5 years;&#xD;
&#xD;
          -  Willing to sign the informed consent for participation and publication of results.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Human epidermal growth factor receptor 2 (HER2)-positive or indeterminate G/GEJ&#xD;
             cancer;&#xD;
&#xD;
          -  Pregnant or lactating women;&#xD;
&#xD;
          -  Positive pregnancy test for women in childbearing age. Menopausal women without&#xD;
             menstruation for at least 12 months can be regarded as women with no possibility of&#xD;
             getting pregnant;&#xD;
&#xD;
          -  Refusal of birth control during the study;&#xD;
&#xD;
          -  Prior chemotherapy, radiotherapy or immunotherapy;&#xD;
&#xD;
          -  History of other malignant diseases in the last 5 years (except for cervical carcinoma&#xD;
             in situ);&#xD;
&#xD;
          -  History of uncontrolled central nervous system diseases, which could influence the&#xD;
             compliance;&#xD;
&#xD;
          -  History of severe liver diseases (Child-Pugh class C), renal diseases (endogenous&#xD;
             creatinine clearance rate (Ccr) ≤ 50 ml/min or SCr &gt; 1.5 ULN) or respiratory diseases;&#xD;
             Uncontrolled diabetes and hypertension; Clinically severe heart disease, such as&#xD;
             symptomatic coronary heart disease, New York Heart Association (NYHA) class II or more&#xD;
             severe congestive heart failure, uncontrolled arrhythmia requiring drug intervention,&#xD;
             or a history of myocardial infarction in the last 6 months;&#xD;
&#xD;
          -  History of dysphagia, complete or partial gastrointestinal obstruction, active&#xD;
             gastrointestinal bleeding and gastrointestinal perforation;&#xD;
&#xD;
          -  On steroid treatment after organ transplant;&#xD;
&#xD;
          -  With uncontrolled severe infections;&#xD;
&#xD;
          -  Known dihydropyrimidine dehydrogenase deficiency (DPD);&#xD;
&#xD;
          -  Anaphylaxis to any research drug ingredient;&#xD;
&#xD;
          -  Known peripheral neuropathy (&gt; NCI-CTC AE 1). Patients with only disappearance of deep&#xD;
             tendon reflex need not to be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xinxin Wang, Dr.</last_name>
    <phone>+8613811858199</phone>
    <email>301wxx@sina.com</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2021</study_first_posted>
  <last_update_submitted>August 15, 2021</last_update_submitted>
  <last_update_submitted_qc>August 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Lin Chen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

